{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Carcinosarcoma&page=3", "query": { "condition": "Endometrial Carcinosarcoma", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 54, "total_pages": 6, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Carcinosarcoma&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Endometrial+Carcinosarcoma&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T03:37:33.304Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06840886", "title": "A Study of PHST001 in Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Ovarian Cancer", "Endometrial Cancer", "Cholangiocarcinoma", "CNS Tumor", "Breast Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Carcinoma", "Carcinosarcoma, Ovarian" ], "interventions": [ { "name": "PHST001", "type": "BIOLOGICAL" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Topotecan", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "FOLFIRI", "type": "DRUG" }, { "name": "FOLFOX", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Mirvetuximab Soravtansine", "type": "BIOLOGICAL" }, { "name": "Trastuzumab Deruxtecan", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Pheast Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 426, "start_date": "2025-03-31", "completion_date": "2031-04", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 20, "location_summary": "Beverly Hills, California • Los Angeles, California • Palo Alto, California + 15 more", "locations": [ { "city": "Beverly Hills", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT06840886" }, { "nct_id": "NCT00005643", "title": "Chemotherapy in Treating Patients With Sarcoma of the Uterus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Sarcoma" ], "interventions": [ { "name": "pegylated liposomal doxorubicin hydrochloride", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gynecologic Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "FEMALE", "summary": "21 Years and older · Female only" }, "enrollment_count": null, "start_date": "2000-05", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-06-10", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 48, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 41 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Gatos", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00005643" }, { "nct_id": "NCT02020707", "title": "Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cervical Adenocarcinoma", "Cervical Adenosarcoma", "Cervical Adenosquamous Carcinoma", "Cervical Carcinosarcoma", "Cervical Squamous Cell Carcinoma", "Clinical Stage IV Cutaneous Melanoma AJCC v8", "Endometrial Adenosquamous Carcinoma", "Endometrial Clear Cell Adenocarcinoma", "Endometrial Endometrioid Adenocarcinoma", "Endometrial Mixed Cell Adenocarcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Endometrial Undifferentiated Carcinoma", "Fallopian Tube Adenocarcinoma", "Fallopian Tube Carcinosarcoma", "Fallopian Tube Clear Cell Adenocarcinoma", "Fallopian Tube Endometrioid Adenocarcinoma", "Fallopian Tube Mucinous Adenocarcinoma", "Fallopian Tube Serous Adenocarcinoma", "Fallopian Tube Squamous Cell Carcinoma", "Fallopian Tube Transitional Cell Carcinoma", "Fallopian Tube Undifferentiated Carcinoma", "Malignant Female Reproductive System Neoplasm", "Malignant Ovarian Clear Cell Tumor", "Malignant Ovarian Endometrioid Tumor", "Malignant Ovarian Epithelial Tumor", "Malignant Ovarian Mucinous Tumor", "Malignant Peritoneal Neoplasm", "Malignant Solid Neoplasm", "Ovarian Carcinosarcoma", "Ovarian Clear Cell Adenocarcinoma", "Ovarian Endometrioid Adenocarcinoma", "Ovarian High Grade Serous Adenocarcinoma", "Ovarian Mucinous Adenocarcinoma", "Ovarian Serous Adenocarcinoma", "Ovarian Transitional Cell Carcinoma", "Ovarian Undifferentiated Carcinoma", "Platinum-Resistant Fallopian Tube Carcinoma", "Platinum-Resistant Ovarian Carcinoma", "Platinum-Resistant Primary Peritoneal Carcinoma", "Platinum-Sensitive Ovarian Carcinoma", "Primary Peritoneal Carcinosarcoma", "Primary Peritoneal Clear Cell Adenocarcinoma", "Primary Peritoneal Serous Adenocarcinoma", "Primary Peritoneal Transitional Cell Carcinoma", "Primary Peritoneal Undifferentiated Carcinoma", "Unresectable Melanoma", "Uterine Corpus Carcinosarcoma" ], "interventions": [ { "name": "Bevacizumab", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nab-paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2014-02-24", "completion_date": "2024-07-18", "has_results": false, "last_update_posted_date": "2024-07-26", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Jacksonville, Florida + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02020707" }, { "nct_id": "NCT05902988", "title": "A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumor", "High Grade Serous Adenocarcinoma of Ovary", "Squamous Non-small-cell Lung Cancer", "Triple Negative Breast Cancer", "Head and Neck Squamous Cell Carcinoma", "Ovarian Carcinosarcoma", "Uterine Carcinosarcoma", "Uterine Serous Carcinoma", "Endometrium Cancer", "Chromosomal Instability" ], "interventions": [ { "name": "VLS-1488", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Volastra Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2023-10-18", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2025-11-04", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 14, "location_summary": "Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Evanston", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05902988" }, { "nct_id": "NCT05049538", "title": "Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in Endometrial Cancers", "overall_status": "RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Endometrial Clear Cell Adenocarcinoma", "Endometrial Dedifferentiated Carcinoma", "Endometrial Mucinous Adenocarcinoma", "Endometrial Serous Adenocarcinoma", "Malignant Uterine Neoplasm", "Uterine Corpus Carcinosarcoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Liquid Biopsy", "type": "PROCEDURE" }, { "name": "Pap Smear", "type": "OTHER" } ], "intervention_types": [ "PROCEDURE", "OTHER" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 1000, "start_date": "2019-06-18", "completion_date": "2028-06-30", "has_results": false, "last_update_posted_date": "2026-10-07", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05049538" }, { "nct_id": "NCT03120624", "title": "VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Endometrial Carcinoma", "Recurrent Endometrial Adenocarcinoma", "Recurrent Endometrial Carcinoma", "Recurrent Endometrial Clear Cell Adenocarcinoma", "Recurrent Endometrial Endometrioid Adenocarcinoma", "Recurrent Endometrial Mixed Cell Adenocarcinoma", "Recurrent Endometrial Serous Adenocarcinoma", "Recurrent Endometrial Undifferentiated Carcinoma", "Recurrent Uterine Corpus Carcinosarcoma", "Stage IV Uterine Corpus Cancer AJCC v7" ], "interventions": [ { "name": "Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Fluorine F 18 Tetrafluoroborate", "type": "OTHER" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Recombinant Vesicular Stomatitis Virus-expressing Human Interferon Beta and Sodium-Iodide Symporter", "type": "BIOLOGICAL" }, { "name": "Ruxolitinib Phosphate", "type": "DRUG" }, { "name": "Technetium Tc-99m Sodium Pertechnetate", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL", "DRUG" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 34, "start_date": "2017-09-15", "completion_date": "2028-01-01", "has_results": true, "last_update_posted_date": "2026-07-21", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03120624" }, { "nct_id": "NCT05646316", "title": "Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Diagnostic Imaging Testing", "type": "PROCEDURE" }, { "name": "Excisional Biopsy", "type": "PROCEDURE" }, { "name": "Indocyanine Green Solution", "type": "DRUG" }, { "name": "Minimally Invasive Surgery", "type": "PROCEDURE" }, { "name": "Pelvic Lymphadenectomy", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Sentinel Lymph Node Mapping", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 428, "start_date": "2022-12-07", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2026-11-06", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 55, "location_summary": "Washington D.C., District of Columbia • Coral Gables, Florida • Deerfield Beach, Florida + 41 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Coral Gables", "state": "Florida" }, { "city": "Deerfield Beach", "state": "Florida" }, { "city": "Doral", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05646316" }, { "nct_id": "NCT03015129", "title": "A Study of Durvalumab With or Without Tremelimumab in Endometrial Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endometrial Cancer", "Endometrial Carcinosarcoma", "Endometrial Carcinoma", "Endometrial Cancer Recurrent", "Endometrial Carcinoma, Recurrent" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 80, "start_date": "2017-01", "completion_date": "2022-12-30", "has_results": true, "last_update_posted_date": "2024-02-06", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03015129" }, { "nct_id": "NCT04214067", "title": "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Endometrial Endometrioid Adenocarcinoma", "Stage I Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8", "Stage II Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Brachytherapy", "type": "RADIATION" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "External Beam Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "X-Ray Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "RADIATION", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 164, "start_date": "2020-04-09", "completion_date": "2027-02-05", "has_results": false, "last_update_posted_date": "2026-07-02", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 275, "location_summary": "Birmingham, Alabama • Clovis, California • Concord, California + 195 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Clovis", "state": "California" }, { "city": "Clovis", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04214067" }, { "nct_id": "NCT03902379", "title": "Web-Based Coping and Communication Skills Intervention in Improving Psychological Adaptation in Patients With Gynecological Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Endometrial Carcinoma", "Stage 0 Fallopian Tube Cancer AJCC v7", "Stage I Fallopian Tube Cancer AJCC v6 and v7", "Stage I Ovarian Cancer AJCC v6 and v7", "Stage IA Fallopian Tube Cancer AJCC v6 and v7", "Stage IA Ovarian Cancer AJCC v6 and v7", "Stage IB Fallopian Tube Cancer AJCC v6 and v7", "Stage IB Ovarian Cancer AJCC v6 and v7", "Stage IC Fallopian Tube Cancer AJCC v6 and v7", "Stage IC Ovarian Cancer AJCC v6 and v7", "Stage II Cervical Cancer AJCC v7", "Stage II Fallopian Tube Cancer AJCC v6 and v7", "Stage II Ovarian Cancer AJCC v6 and v7", "Stage II Uterine Corpus Cancer AJCC v7", "Stage IIA Cervical Cancer AJCC v7", "Stage IIA Fallopian Tube Cancer AJCC v6 and v7", "Stage IIA Ovarian Cancer AJCC V6 and v7", "Stage IIA1 Cervical Cancer AJCC v7", "Stage IIA2 Cervical Cancer AJCC v7", "Stage IIB Cervical Cancer AJCC v6 and v7", "Stage IIB Fallopian Tube Cancer AJCC v6 and v7", "Stage IIB Ovarian Cancer AJCC v6 and v7", "Stage IIC Fallopian Tube Cancer AJCC v6 and v7", "Stage IIC Ovarian Cancer AJCC v6 and v7", "Stage III Cervical Cancer AJCC v6 and v7", "Stage III Fallopian Tube Cancer AJCC v7", "Stage III Ovarian Cancer AJCC v6 and v7", "Stage III Primary Peritoneal Cancer AJCC v7", "Stage III Uterine Corpus Cancer AJCC v7", "Stage IIIA Cervical Cancer AJCC v6 and v7", "Stage IIIA Fallopian Tube Cancer AJCC v7", "Stage IIIA Ovarian Cancer AJCC v6 and v7", "Stage IIIA Primary Peritoneal Cancer AJCC v7", "Stage IIIA Uterine Corpus Cancer AJCC v7", "Stage IIIB Cervical Cancer AJCC v6 and v7", "Stage IIIB Fallopian Tube Cancer AJCC v7", "Stage IIIB Ovarian Cancer AJCC v6 and v7", "Stage IIIB Primary Peritoneal Cancer AJCC v7", "Stage IIIB Uterine Corpus Cancer AJCC v7", "Stage IIIC Fallopian Tube Cancer AJCC v7", "Stage IIIC Ovarian Cancer AJCC v6 and v7", "Stage IIIC Primary Peritoneal Cancer AJCC v7", "Stage IIIC Uterine Corpus Cancer AJCC v7", "Stage IIIC1 Uterine Corpus Cancer AJCC v7", "Stage IIIC2 Uterine Corpus Cancer AJCC v7", "Stage IV Cervical Cancer AJCC v6 and v7", "Stage IV Fallopian Tube Cancer AJCC v6 and v7", "Stage IV Ovarian Cancer AJCC v6 and v7", "Stage IV Primary Peritoneal Cancer AJCC v7", "Stage IV Uterine Corpus Cancer AJCC v7", "Stage IVA Cervical Cancer AJCC v6 and v7", "Stage IVA Uterine Corpus Cancer AJCC v7", "Stage IVB Cervical Cancer AJCC v6 and v7", "Stage IVB Uterine Corpus Cancer AJCC v7", "Uterine Carcinosarcoma", "Uterine Corpus Sarcoma" ], "interventions": [ { "name": "Internet-Based Intervention", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Rutgers, The State University of New Jersey", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2016-07-27", "completion_date": "2020-05-31", "has_results": false, "last_update_posted_date": "2021-04-19", "last_synced_at": "2026-11-15T03:37:33.304Z", "location_count": 1, "location_summary": "New Brunswick, New Jersey", "locations": [ { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT03902379" } ] }